Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome

NCT00447993 is registered in ClinicalTrials.gov with Neurotech Pharmaceuticals as lead sponsor.

NCT NCT00447993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00447993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome
Lead sponsor
Neurotech Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 8, 2007
Completion date
May 26, 2009
Enrollment
67 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa